Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Manuscript information
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research ArticleCell biologyOncology Open Access | 10.1172/JCI199747

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models

Jiaxi Song,1 Dan Cui,2 Jiabao Wang,1 Xuewei Qi,1 Jiaxin Ma,1 Haoyu Yu,1 Qing Liu,1 Jing Yang,1 Tengfei Hu,3 Xu Han,3 Handong Ma,1 Rentao Yu,4 Ying Dai,5 Xiaona Zhang,6,7 Qunfa Cao,6,7 Xiaoyuan Song,3 Bofeng Li,1 Lilin Ye,8,9 Hua Wang,5,10 Qizhao Huang,8 Jia Li,2,11,12 and Fengyin Li1

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Song, J. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Cui, D. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Wang, J. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Qi, X. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Ma, J. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Yu, H. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Liu, Q. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Yang, J. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Hu, T. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Han, X. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Ma, H. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Yu, R. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Dai, Y. in: PubMed | Google Scholar |

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Zhang, X. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Cao, Q. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Song, X. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Li, B. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Ye, L. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Wang, H. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Huang, Q. in: PubMed | Google Scholar |

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Li, J. in: PubMed | Google Scholar

1State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

2Guangzhou National Laboratory, Guangzhou, China.

3Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

4Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

5Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

6National Engineering Center for Biochip at Shanghai, Shanghai, China.

7Shanghai Biochip Corporation, Shanghai, China.

8Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.

9Changping Laboratory, Beijing, China.

10Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Hefei, China.

11State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

12China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University. Guangzhou, China.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Authorship note: JS and DC are co–first authors.

Find articles by Li, F. in: PubMed | Google Scholar

Authorship note: JS and DC are co–first authors.

Published November 16, 2026 - More info

Published in Volume 136, Issue 22 on November 16, 2026
J Clin Invest. 2026;136(22):e199747. https://doi.org/10.1172/JCI199747.
© 2026 Song et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 16, 2026 - Version history
Received: September 2, 2025; Accepted: September 22, 2026
View PDF
Abstract

T follicular helper (TFH) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling TFH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of TFH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13hi TFH cells, and its deficiency impaired TFH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key TFH-associated loci, including Cxcr5 and Il6ra. Notably, ginkgolic acid treatment suppressed TFH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during TFH differentiation and suggest that modulation of this pathway may provide a strategy to tune TFH-driven immune responses.

Introduction

T follicular helper (TFH) cells, a specialized CD4+ T cell subset, serve as coordinators of germinal center (GC) responses, providing crucial help to B cells for survival, proliferation, class switching, and affinity maturation to generate effective antibodies (1–3). These functions are pivotal for protection against infectious diseases and cancer. In viral infections, such as lymphocytic choriomeningitis virus (LCMV) and influenza, TFH cells are indispensable for the generation of high‑affinity neutralizing antibodies and the establishment of long‑term humoral memory (4, 5). In the tumor microenvironment, TFH cells contribute to the formation and function of tertiary lymphoid structures and are associated with favorable clinical outcomes and enhanced responses to immune checkpoint blockade (6, 7). However, the benefits of TFH cells are also double‑edged in immune checkpoint inhibitor (ICI) therapy. Because they express high levels of PD‑1, anti–PD-1 therapy directly promotes TFH expansion and differentiation, leading to excessive B cell help, autoantibody production, and tissue‑directed inflammation via IL‑21 and CXCL13 (8). Clinically, TFH expansion correlates with immune‑related adverse event development, positioning TFH cells as a key link between ICI efficacy and autoimmune toxicity (9, 10). Therefore, identifying a target that suppresses aberrant TFH expansion without compromising the antitumor efficacy of ICIs is of critical importance.

The differentiation and function of TFH cells are tightly controlled at multiple levels, including transcriptional regulation, signaling pathways, and epigenetic modifications. The transcription factor TCF1 (encoded by Tcf7) has been established as a master regulator of TFH cell differentiation, promoting the expression of key TFH-associated genes such as Cxcr5, Pdcd1, and Bcl6 (11–13). Additionally, the chromatin landscape and 3D genome organization play crucial roles in establishing cell-type–specific transcriptional programs during TFH differentiation (14, 15). However, the epitranscriptomic mechanisms that modulate TFH cell differentiation and function remain poorly understood.

RNA modifications have emerged as critical posttranscriptional regulators of gene expression in immune cells. Among these, 3-methylcytosine (m³C) is a recently characterized modification that occurs on both mitochondrial and cytosolic tRNAs, as well as on mRNAs (16–19). METTL8 has been identified as a methyltransferase that catalyzes m³C modification on specific tRNAs and regulates mitochondrial protein translation and respiration (16–18). However, whether METTL8 plays a role in CD4+ T cell differentiation, particularly in the TFH lineage, has not been explored.

In this study, we identified METTL8 as a regulator of TFH cell differentiation in viral infection and tumor immunotherapy models. We found that METTL8 is highly expressed in inflammatory CD4+CXCL13+ TFH cells. Using the acute LCMV infection model and MC38 and B16F10 tumor models, we demonstrated that METTL8-mediated m³C modification is important for TFH differentiation and GC responses in both contexts. Mechanistically, our data support a model in which METTL8 stabilizes Tcf7 mRNA in an m³C-associated manner and cooperates with TCF1 protein to regulate genome-specific chromatin loops and enhance chromatin accessibility at key TFH loci. Furthermore, we show that GA suppresses TFH responses in a METTL8-associated manner without compromising the antitumor efficacy of anti–PD-1 therapy. Collectively, our findings identify METTL8 as a key epitranscriptomic regulator of TFH cell differentiation, providing potential avenues for modulating TFH responses in immunological disorders.

Results

METTL8 is highly expressed in CXCL13hi CD4+ T cells. Although ICIs have achieved therapeutic success in various malignancies, their administration drives marked expansion of CD4+ T cells and can elicit autoimmune‑like tissue manifestations, with the skin being one of the most frequently affected sites. To characterize the CD4+ T cell populations induced by anti–PD‑1 therapy, we collected skin samples from patients with tumors who had developed dermatitis after anti–PD-1 treatment and performed spatial transcriptome sequencing (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI199747DS1). The data revealed CD4 expression in the skin samples (Figure 1A and Supplemental Figure 1B). As CXCL13 is expressed in CD4+ T cells within autoimmune-affected organs (20), we detected CXCL13 expression in many CD4+ regions of the skin samples (Figure 1A and Supplemental Figure 1B) (21). PDCD1, the characteristic marker of GC TFH cells, was also detected in tissue regions enriched for CD4 and CXCL13 expression (Figure 1A and Supplemental Figure 1B), suggesting the presence of TFH-like CD4+ cells in these areas. To further explore CXCL13 expression in the TFH cells generated by anti–PD-1 therapy, we treated B16F10 tumor–bearing mice with anti–PD-1 antibody and tested TFH cells in their spleens and tumor-draining lymph nodes (TdLNs) (Figure 1B). Anti–PD-1 treatment significantly suppressed tumor growth (Supplemental Figure 1, C and D). Compared with IgG-treated controls, anti–PD-1–treated mice exhibited markedly increased frequencies of GC TFH cells in both spleens and TdLNs (Figure 1C and Supplemental Figure 1E). Notably, anti–PD-1 treatment significantly increased the absolute number of CXCL13hi GC TFH cells and modestly increased their frequency (Figure 1D and Supplemental Figure 1F), and CXCL13 expression levels were substantially elevated in TFH cells following anti–PD-1 treatment (Figure 1E and Supplemental Figure 1G). Collectively, these results indicate that anti–PD-1 treatment expands the population of CXCL13hi TFH cells.

METTL8 is expressed in CXCL13hi CD4+ T cells.Figure 1

METTL8 is expressed in CXCL13hi CD4+ T cells. (A) Spatial expression of CD4, CXCL13, and PDCD1 in skin lesions from patients with anti–PD-1 treated tumors. (B) Schematic diagram of mouse model: B16F10 cells were subcutaneously injected into B6 mice and intraperitoneally injected with anti–PD-1 or IgG every 2 days from days 8 to 12, then analyzed at day 14. (C) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (gated on CD44hiCD62Llo CD4+ T cells) in the TdLNs of non-tumor, IgG‑, or anti–PD‑1–treated tumor mice (n = 5/group). (D) Frequency and absolute number of CXCL13hi cells (gated on BCL6+CXCR5+ GC TFH cells) in TdLNs of B16F10 tumor–bearing mice treated with IgG or anti–PD‑1 (n = 8–9/group). (E) MFI of CXCL13 in BCL6+CXCR5+ TFH cells in the TdLNs of B16F10 tumor–bearing mice treated with IgG or anti–PD‑1 (n = 7/group). (F) Mettl8-tdTomato-Flag mice were infected with LCMV-Armstrong and analyzed at 8 dpi. Splenic CD44hiCD62Llo CD4+ cells were gated; CXCL13 expression is shown for PD-1hiCXCR5hi GC TFH, PD-1loCXCR5+ TFH, and CXCR5− non-TFH subsets (n = 3/group). (G) Bubble plot of selected TFH/TH1-related differentially expressed genes between CXCL13hi and CXCL13lo clusters. (H) Heatmap of top 50 differentially expressed genes between CD4+ T cells from patients with SS versus healthy controls (scRNA-seq). (I) Cross-comparison of gene expression changes in CD4+ T cells from patients with disease versus healthy controls and in TFH versus TH1 cells. Selected genes shared between the 2 comparisons are highlighted. Mouse data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 1-way ANOVA (C and F) and 2-tailed Student’s t test (D and E). *P < 0.05; ***P < 0.001; ****P < 0.0001.

Given that cancer immunotherapy elicits autoimmune responses characterized by expansion of CXCL13hi GC TFH cells, which share similar features with spontaneous autoimmune diseases, and that GC TFH cells in the classic LCMV mouse infection model also express high levels of CXCL13 (Figure 1F), we sought to identify key epitranscriptomic regulators that commonly govern these cells. Therefore, we compared CD4+ T cells from the salivary glands of patients with Sjögren’s syndrome (SS), a spontaneous autoimmune disease, with those from healthy individuals treated as controls and performed integrative analysis with differentially expressed genes between TFH and TH1 cells from the classical LCMV mouse infection model.

By reanalyzing published scRNA-seq data from salivary glands in healthy individuals and patients with SS (22), we identified 4 CD4+ T cell clusters, including proliferating CD4+ T cells, Treg cells, CXCL13hi, and CXCL13lo CD4+ T cells (Supplemental Figure 1I). To depict the characteristics of the latter 2 clusters, we analyzed the differentially expressed genes between these cells and found that CXCL13hi CD4+ T cells highly expressed TFH-featured genes, such as CXCR5, PDCD1, BCL6, and TCF7, while CXCL13lo CD4+ T cells were prone to TH1 cells (Figure 1G). Further analysis of differentially expressed genes revealed that these highly expressed TFH-associated genes were also enriched in the CD4+ T cells of patients with SS compared with healthy individuals (Figure 1H), suggesting that these CXCL13hi TFH cells increased in affected organs of the autoimmune disease. These results further support the presence of CXCL13hi TFH-like cells with B cell helper features in autoimmune-affected tissues.

To identify factors potentially involved in TFH cell development, we performed a cross-analysis of genes highly expressed in TFH cells from the canonical LCMV-infected mouse model (11) and those upregulated in CXCL13hi CD4+ T cells from patients with SS. The overlapping gene set predominantly comprised known TFH-associated genes, including CXCR5, TCF7, and PDCD1. Notably, METTL8, which encodes an m³C methyltransferase and has not previously been implicated in TFH cell biology, was also present among the common genes (Figure 1I). These findings suggest that METTL8 may serve as a shared regulator of CXCL13hi TFH cells across distinct pathological and physiological contexts. Further analysis revealed that METTL8 was highly expressed in CD4+ T cells of patients with SS compared with those of healthy individuals, which is consistent with the expression of CXCL13 (Figure 1I). Thus, we hypothesize that METTL8 contributes to CXCL13hi TFH cell specification.

To determine whether METTL8 is expressed in TFH cells following ICI treatment, we first analyzed transcriptomic data from skin samples and observed high METTL8 expression in the CD4+CXCL13+PD-1+ regions (Figure 2A). We then examined METTL8 expression in the CD4+BCL6+ TFH cells within skin samples from patients with anti–PD-1–treated tumors. Compared with untreated controls, anti–PD-1–treated patients exhibited increased CD4+ T cell infiltration in the skin. Notably, these infiltrating CD4+ T cells expressed both BCL6 and METTL8, whereas such cells showed little or no detectable staining for these markers in untreated controls (Figure 2B and Supplemental Figure 2A). Collectively, these findings indicate that METTL8 is expressed in TFH cells upon anti–PD-1 therapy.

METTL8 is commonly expressed in CXCL13hi CD4+ T cells among diverse patholoFigure 2

METTL8 is commonly expressed in CXCL13hi CD4+ T cells among diverse pathological and experimental settings. (A) The distribution and expression of METTL8 in the skin of patients with anti–PD-1–treated tumors by spatial transcriptome sequencing. (B) The expression of CD4, Bcl6, and METTL8 in the skin from anti–PD-1–treated or untreated tumor patients by immunofluorescence. Scale bars: 100 μm. (C) Schematic of the mouse model: B16F10 cells were subcutaneously injected into Mettl8-tdTomato-Flag mice and intraperitoneally injected with anti–PD-1 or IgG every 2 days from days 7 to 11, then analyzed at day 13. (D) The MFI of Mettl8-tdTomato reporter in PD-1hiCXCR5hi GC TFH cells in the spleens of anti–PD-1– or IgG-treated B16F10 tumor–bearing mice (n = 6/group). (E) Schematic of the mouse model: Mettl8-tdTomato-Flag mice were intraperitoneally injected with 2 × 105 PFU LCMV-Armstrong and analyzed at 8 dpi. (F) Representative plots and quantification illustrating the expression of Mettl8-tdTomato gated on PD-1hiCXCR5hi GC TFH cells, PD-1loCXCR5+ TFH cells, and CXCR5− non-TFH cells (n = 5/group). (G) Representative histogram and quantification of Mettl8-tdTomato MFI in CXCL13hi and CXCL13lo CD4+ T cell subsets (n = 3/group). (H) Violin plots displaying the expression of CXCL13 and METTL8 within healthy controls and patients with SS. (I) Bubble plots displaying the expression of METTL8 within CXCL13hi and CXCL13lo clusters from scRNA-seq analysis. Mouse data represent 2–3 independent experiments; mean ± SEM. P values were calculated using a 2-tailed Student’s t test. **P < 0.01; ***P < 0.001; ****P < 0.0001.

To further validate this observation, we inoculated B16F10 cells into Mettl8-tdTomato-Flag reporter mice and treated them with either IgG or anti–PD-1 antibody (Figure 2C). Analysis of PD-1hiCXCR5hi GC TFH cells in the spleens and TdLNs revealed that METTL8 expression levels were higher in anti–PD-1–treated mice than in IgG-treated controls (Figure 2D and Supplemental Figure 2B). Taken together, these results support the conclusion that METTL8 is expressed in TFH cells following treatment in both human and mouse samples.

To further investigate whether METTL8 is expressed preferentially in TFH cells, we infected Mettl8-tdTomato-Flag mice with LCMV-Armstrong and analyzed them at 8 days after infection (Figure 2E). We confirmed that Mettl8-tdTomato was highly expressed in PD-1hiCXCR5hi GC TFH cells compared with PD-1loCXCR5+ TFH cells or CXCR5− non-TFH cells (Figure 2F). Considering these consistent expression trends of CXCL13 and METTL8 in both the human disease and the mouse model, we conducted further analysis that revealed that the expression of METTL8 was much higher in CXCL13hi CD4+ T cells than in CXCL13lo CD4+ T cells (Figure 2G). These results indicate that METTL8 is preferentially expressed in CXCL13hi GC TFH cells.

Further analysis revealed that METTL8 expression was significantly higher in CD4+ T cells of SS patients than in those from healthy controls, a pattern consistent with CXCL13 expression (Figure 2H). In addition, METTL8 expression was markedly elevated in CXCL13hi clusters compared with CXCL13lo clusters (Figure 2I). These findings suggest that METTL8 may contribute to the specification of CXCL13hi TFH cells.

METTL8 promotes TFH cell differentiation. To further explore whether METTL8 promotes TFH cell generation by tumor immunotherapy, we subcutaneously inoculated B16F10 or MC38 cells into Mettl8fl/fl Cd4cre mice and littermate controls and then treated mice with anti–PD-1 antibody or IgG (Figure 3A). The data showed that Mettl8 deficiency did not affect the frequency and absolute number of CD4+ T cells in either spleens or TdLNs (Supplemental Figure 3, A and B). CD4+ T cell activation was also not detectably affected by Mettl8 deficiency (Supplemental Figure 3, C and D). However, PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells were decreased in Mettl8-deficient mice compared with littermate controls after anti–PD-1 treatment in both spleens and TdLNs (Figure 3B and Supplemental Figure 3, E and F). Thus, these data indicate that METTL8 promotes TFH cell accumulation after anti–PD-1 treatment.

METTL8 promotes TFH cell differentiation.Figure 3

METTL8 promotes TFH cell differentiation. (A) Schematic diagram of the mouse model: 2 × 105 B16F10 cells were subcutaneously injected into Mettl8fl/fl Cd4cre and littermate control mice and intraperitoneally injected with anti–PD-1 or IgG every 2 days from days 7 to 11. Mice were analyzed at day 13. (B) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells gated on CD44hiCD62Llo CD4+ T cells in the TdLNs of B16F10 tumor–bearing Mettl8fl/fl Cd4cre and littermate control mice treated with IgG or anti–PD‑1 antibody (n = 5–8/group). (C) Schematic of adoptive transfer: CD45.1+ Mettl8−/− or Ctrl Smarta CD4+ T cells were transferred into CD45.2+ WT recipients, followed by LCMV-Armstrong (LCMV-Arm) 24 h later, and analyzed at 8 dpi. (D) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells in CD45.1+ Smarta CD4+ T cells in spleens of WT recipients (n = 8/group). (E) Schematic of the cotransfer experiment. CD45.2+ Mettl8−/− or Ctrl Smarta CD4+ T cells were primed in vivo for 24 h and transduced with EV-GFP or Mettl8-GFP retrovirus. GFP+ and GFP− cells were sorted and cotransferred at a 1:1 ratio into CD45.1+ WT recipients, followed by LCMV-Armstrong infection 24 h later and analyzed at 8 dpi. (F) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells gated on CD45.2+ Smarta CD4+ T cells in the spleens of mice in E (n = 6/group). Cell counts were normalized to the corresponding WT GFP– group within each experiment. Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 1-way ANOVA (B and F) and 2-tailed Student’s t test (D). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

To further validate the effect of METTL8 on TFH cells, we used the canonical LCMV-infected mouse model. Mettl8fl/fl Cd4cre mice were crossed with a Smarta TCR transgenic strain expressing an MHC II–restricted TCR specifically recognizing the LCMV gp61 epitope. WT and Mettl8−/− Smarta CD4+ T cells were adoptively transferred into congenic recipients, followed by infection with LCMV-Armstrong (Figure 3C). In response to infection, Mettl8−/− Smarta CD4+ T cells exhibited a marked decrease in PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (Figure 3D). Furthermore, LCMV infection showed no difference between the frequencies and absolute numbers of CD44hiCD62lo activated CD4+ T cells of Mettl8fl/fl Cd4cre mice and littermate controls (Supplemental Figure 4A), but GC TFH cells were impaired by Mettl8 deficiency (Supplemental Figure 4, B and C). In addition, we observed a reduction in SLAMloCXCR5+ TFH cells among monoclonal and polyclonal CD4+ T cells, accompanied by increased frequencies and unchanged counts of SLAMhiCXCR5− TH1 cells (Supplemental Figure 4, D and E). The PD-1loCXCR5+ TFH cells were also reduced by Mettl8 deficiency, whereas the number of CXCR5− non-TFH cells was not affected, although the frequency increased (Supplemental Figure 4F). Notably, the expression of caspase and Ki67 in TFH cells was unaffected by Mettl8 deficiency, suggesting that METTL8 does not affect apoptosis or proliferation of TFH cells (Supplemental Figure 4G). Therefore, these results indicate that Mettl8 deficiency impairs TFH cell differentiation.

To further substantiate the requirement of METTL8 in TFH cell differentiation, we enforced METTL8 expression in Mettl8−/− or control (Ctrl) Smarta CD4+ T cells using pMSCV-IRES-GFP retroviruses. GFP+ and GFP− cells were sorted and cotransferred into recipient mice at a 1:1 ratio (Figure 3E and Supplemental Figure 4H). Mice were infected with LCMV-Armstrong, and at the 8 day postinfection (dpi) time point, the ratio of GFP+ to GFP− cells remained unaltered (Supplemental Figure 4I), indicating comparable survival and proliferation of transduced and nontransduced cells. Relative to empty vector–GFP (EV-GFP) control, forced expression of METTL8 in Ctrl Smarta cells significantly increased PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (Figure 3F). Importantly, ectopic METTL8 expression in Mettl8−/− Smarta cells significantly rescued the reduction in GC TFH cells caused by Mettl8 deficiency (Figure 3F). Moreover, SLAMloCXCR5+ TFH cells were restored, and the frequency of SLAMhiCXCR5− TH1 cells was decreased by METTL8 overexpression in Mettl8−/− Smarta cells (Supplemental Figure 4J). These data further support a requirement for METTL8 in TFH cell differentiation.

METTL8 promotes TFH cell function. To assess the impact of Mettl8-deficient TFH cells on tumor progression, we monitored tumor growth and survival in MC38 or B16F10 tumor–bearing Mettl8fl/fl Cd4cre mice and littermate controls. Antitumor responses, with or without anti–PD-1 treatment, were comparable between genotypes in these models (Figure 4, A and B, and Supplemental Figure 5, A and B). Given the essential role of TFH cells in supporting B cell responses, we next examined the GC response in TdLNs. Upon anti–PD-1 treatment, Mettl8 deficiency led to a reduction in GC B cells and plasma cells within TdLNs (Figure 4C and Supplemental Figure 5C). Collectively, these data indicate that Mettl8 deficiency impairs the GC response in TdLNs following anti–PD-1 therapy, without affecting tumor progression.

METTL8 promotes TFH cell function.Figure 4

METTL8 promotes TFH cell function. (A and B) Tumor growth (A) and survival (B) of MC38-bearing Mettl8fl/fl Cd4cre and littermate controls, treated with IgG or anti–PD-1 (n = 8/group). (C) Representative plots (left) and quantification (right) of GL-7+Fas+ GC B cells and CD138+IgDlo plasma cells (gated on B220+CD19+ cells) in the TdLNs of the above groups (n = 4–8/group). (D) Schematic of the adoptive transfer model: CD45.1+ Mettl8−/− or Ctrl Smarta CD4+ T cells were transferred into CD45.2+ Bcl6fl/fl Cd4cre recipients, followed by LCMV-Armstrong 24 h later, and analyzed at 14 dpi. (E and F) Representative plots (E) and quantification (F) of GC B cells and plasma cells in the spleens of the mice in D (n = 7–8/group). (G) Immunofluorescence of spleens from LCMV-Armstrong–infected Mettl8fl/fl Cd4cre mice and littermate controls at 8 dpi, indicating B cell follicle (green) and GC (red). Scale bars: 100 μm. (H) LCMV-specific IgG in serum of mice in D by ELISA (n = 5/group). (I) Serum samples were collected from Mettl8−/− or Ctrl Smarta cell–transferred mice at 4 dpi with LCMV‑Armstrong. Viral titers of the sera were quantified by qPCR using 2 independent primer pairs targeting the LCMV glycoprotein (GP) and nucleoprotein (NP) genes (n = 9–10/group). (J) Liver samples were collected from Mettl8−/− or Ctrl Smarta cell–transferred mice at 8 dpi with LCMV‑Armstrong. H&E staining showing inflammatory cell infiltration (arrows) in indicated groups. Scale bars: 200 μm (left), 50 μm (right). Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 2-way ANOVA (A), log-rank test (B), 1-way ANOVA (C), and 2-tailed Student’s t test (F, H, and I), *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

To examine the functional requirement of METTL8 in the infection model, we transferred Mettl8−/− or Ctrl Smarta CD4+ T cells to Bcl6fl/fl Cd4cre mice, which were deficient in endogenous GC TFH cells (Figure 4D) (23). Mettl8-deficient PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells were dramatically reduced at 14 dpi (Supplemental Figure 5, D and E). Accordingly, recipients of Mettl8−/− Smarta cells exhibited reduced Fas+GL7+ GC B cells and CD138+IgDlo plasma cells (Figure 4, E and F). Similarly, direct LCMV-Armstrong infection of Mettl8fl/fl Cd4cre mice resulted in decreased GC B cells and plasma cells at 8 dpi compared with littermate controls (Supplemental Figure 5, F and G), and GC formation was impaired (Figure 4G). Consistently, LCMV-specific IgG in the serum of Bcl6fl/fl Cd4cre recipients was significantly reduced by Mettl8 deficiency (Figure 4H). Furthermore, Mettl8 deficiency led to elevated viral loads (Figure 4I). Although LCMV-Armstrong infection normally induces only mild hepatitis in mice (24), representative H&E images showed more prominent inflammatory infiltrates in portal tracts and intralobular regions (Figure 4J). Histological examination further revealed that follicle-associated regions were diminished in the spleens of Mettl8−/− Smarta cell–transferred mice (Supplemental Figure 5H). These data support an important role for METTL8 in GC responses.

METTL8 promotes TFH cell accumulation and maintenance. As TH1 and TFH fate determination occurs promptly following the activation of CD4+ T cells, we investigated the potential involvement of METTL8 in the TFH fate decision process. Initially, we assessed METTL8 expression in activated CD4+ T cells in vitro, observing heightened expression with prolonged stimulation (Supplemental Figure 6A). To further explore METTL8 expression, we utilized Mettl8-tdTomato Smarta CD4+ T cells labeled with cell-trace violet and adoptively transferred them into congenic recipients, followed by LCMV-Armstrong infection (Supplemental Figure 6B). Harvesting cells at the 40 and 60 h postinfection (hpi) time point, corresponding to the initiation of the first division at 36 hpi and the fifth division at 60 hpi (25) for Smarta CD4+ T cells, we examined METTL8 expression in each division from the first to the fifth (Supplemental Figure 6C). The data revealed elevated METTL8 expression during CD4+ T cell activation and the first division, maintaining a sustained high level despite slight decreases during subsequent divisions (Figure 5A). These results indicate that METTL8 expression is increased by CD4+ T cell activation during the early TH1-TFH fate bifurcation stage, prompting us to investigate whether METTL8 plays a role during this period.

Mettl8 deficiency impairs TFH differentiation due to altered transcriptionaFigure 5

Mettl8 deficiency impairs TFH differentiation due to altered transcriptional profiles. (A) Representative plots (top) and quantification (bottom) of MFI of tdTomato in each division (Div) of CD45.2+ Smarta CD4+ T cells. All the MFI of tdTomato in divisions 1–5 are compared with that in division 0 (n = 4–10/group). (B) Representative plots (left) and quantification (right) of the frequency of CXCR5+SLAMlo TFH and CXCR5−SLAMhi TH1 cells in the spleens of Mettl8−/− or Ctrl Smarta cell–transferred mice at 4–7 dpi with LCMV‑Armstrong (n = 3–4/group). (C–F) RNA-seq was conducted on PD-1hiCXCR5hi GC TFH cells sorted from spleens of LCMV-Armstrong–infected Mettl8fl/fl Cd4cre (KO) mice and littermate controls (WT) at 8 dpi. In C, Volcano plot illustrates DEGs between GC TFH cells from KO and WT mice. Lines indicate a 2-fold difference between GC TFH cells from KO and WT mice (edgeR, FDR < 0.05). In D, KEGG analysis of DEGs obtained from the R package named clusterProfiler. In E, GSEA shows the enrichment of TFH versus non-TFH cell-associated downregulated (top) and upregulated (bottom) genes in the transcriptome of KO versus WT GC TFH cells. In F, heatmap displaying DEGs related to TFH and TH1 cells. (G) Representative histograms (top) and cumulative data (bottom) showing the expression of the indicated molecules gated on PD-1hiCXCR5hi GC TFH cells (n = 4–8/group). For mouse experiments, data represent 2–3 independent experiments; mean ± SEM. P values were calculated using a 2-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

To explore the role of METTL8 in TFH lineage specification, we utilized Mettl8fl/fl Cd4cre mice and littermate controls. Following adoptive transfer of cell-trace violet–labeled Mettl8−/− or Ctrl Smarta CD4+ T cells and LCMV-Armstrong infection, both groups underwent at least 5 divisions, with the majority of cells in the fourth and fifth divisions at 60 hpi, indicating comparable division rates (Supplemental Figure 6D). These findings suggest that the loss of METTL8 does not disrupt CD4+ T cell activation and early division. Despite this, the reduction of TFH cells upon Mettl8 deficiency led us to infer that METTL8 may contribute to TFH versus TH1 lineage bifurcation.

As previously reported, the combination of CD25 and CXCR5 was employed to distinguish nascent TH1 and TFH cells in activated CD4+ T cells (25). In the fifth division, Mettl8−/− CD25loCXCR5+/lo nascent TFH cells were detected at a lower frequency compared with their WT counterparts, accompanied by an opposite change in the frequency of CD25hiCXCR5− nascent TH1 cells (Supplemental Figure 6E). Additionally, CXCR5 expression was slightly but significantly reduced in Mettl8-deficient nascent TFH cells, whereas it remained unchanged in nascent TH1 cells (Supplemental Figure 6E). These results suggest that METTL8 exerts modest effects on early TFH specification. We therefore examined TFH cells from days 4 to 7 after infection and found that the reduction in TFH cells caused by Mettl8 deficiency became progressively more pronounced over time (Figure 5B and Supplemental Figure 6F). Consequently, our findings indicate that METTL8 has a limited impact on early TFH differentiation but plays a substantial role in TFH accumulation and maintenance.

To unravel the underlying mechanism governing TFH cell development mediated by METTL8, we conducted RNA sequencing on sorted PD-1hiCXCR5hi GC TFH cells obtained from LCMV-Armstrong–infected Mettl8fl/fl Cd4cre mice and their littermate controls at 8 dpi. Our analysis identified 1,597 downregulated genes and 1,469 upregulated genes in Mettl8-deficient GC TFH cells, each exhibiting a fold change > 2 (Figure 5C). Notably, these differentially expressed genes showed enrichment in pathways related to TFH cell differentiation (Figure 5D). GSEA further revealed that genes downregulated in TFH cells compared with non-TFH cells were enriched in Mettl8-deficient GC TFH cells, while genes upregulated in TFH cells versus non-TFH cells were enriched in WT GC TFH cells (Figure 5E). Among the identified upregulated and downregulated genes, those encoding transcription factors crucial for TFH cell differentiation, such as Bcl6, Maf, Tcf7, Cebpa, Tox, Id3, Pou2af1, Sostdc1, and Ascl2, were consistently downregulated in Mettl8-deficient GC TFH cells (Figure 5F and Supplemental Figure 6G). Additionally, the expression of genes defining GC TFH cell characteristics, including Cxcr5, Pdcd1, Icos, and Il21, exhibited a decrease in Mettl8-deficient mice (Figure 5F and Supplemental Figure 6G). Consistent with our RNA-seq findings, flow cytometric analysis confirmed a significant reduction in the expression of TFH cell surface markers CXCR5 and ICOS, as well as transcription factors BCL6 and TCF1 (Figure 5G). Conversely, genes upregulated in Mettl8-deficient GC TFH cells tended to exhibit TH1 signatures, including Prdm1, Tbx21, Id2, and Il2ra (Figure 5F and Supplemental Figure 6G). The increased expression of T-bet was validated by flow cytometry (Figure 5G). In summary, these results indicate that METTL8 biases activated CD4+ T cells toward the TFH program rather than the TH1 program.

METTL8 facilitates m3C-associated regulation of Tcf7 mRNA and cooperates with TCF1-associated chromatin programs. To elucidate the mechanisms by which METTL8-mediated m3C methylation modulates the TFH transcriptional program, we conducted AlkAniline-seq (26) to identify distinct m3C modification loci between PD-1hiCXCR5hi GC TFH cells isolated from LCMV-Armstrong–infected Mettl8fl/fl Cd4cre mice and littermate controls. The global mapping of the m3C landscape revealed abundant m3C peaks within the coding sequence of mRNA (Supplemental Figure 7, A and B). Comparative analysis of m3C modification loci in Mettl8-deficient and WT GC TFH cells identified 4,491 different sites, with 1,425 in WT TFH cells and 3,066 in Mettl8-deficient TFH cells (Supplemental Figure 7C). Significantly enriched RNA motifs flanking m³C modification loci from WT GC TFH cells are presented (Supplemental Figure 7D). These data revealed AlkAniline-seq for mapping m3C modifications in TFH cells.

Given that METTL8 is a mitochondrially localized enzyme that catalyzes m3C modification on tRNAs and regulates mitochondrial protein translation and respiration (16–18), we first performed tRNA m³C-seq to examine whether Mettl8 deficiency affects tRNA modification in TFH cells. However, we observed no significant differences in tRNA m³C modification between WT and Mettl8-deficient TFH cells (Supplemental Figure 7, F and G). To further assess mitochondrial respiratory function, we performed Seahorse metabolic flux analysis in WT and Mettl8-deficient TFH cells. No statistically significant differences were detected in the measured bulk oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) parameters under the tested conditions (Supplemental Figure 7H). Collectively, these results suggest that METTL8 does not appreciably affect tRNA m³C modification or global mitochondrial metabolism in TFH cells, prompting us to investigate its potential mRNA-targeted functions.

To further investigate METTL8 binding sites on mRNA, RNA-immunoprecipitation and sequencing (RIP-seq) was performed on PD-1hiCXCR5hi GC TFH cells isolated from LCMV-Armstrong–infected mice. A combined analysis of RNA-seq, m3C-seq, and RIP-seq revealed 94 genes commonly targeted by m3C and METTL8, with differential RNA expression between Mettl8-deficient and WT GC TFH cells (Supplemental Figure 7E). To define a direct relationship between METTL8 binding and differential m³C modification, we required that a METTL8 binding site must be located within 500 bp of a differential m3C modification site on the same transcript (27, 28), rather than merely co-occurring anywhere on the same transcript. To evaluate the biological significance of the observed overlap, we performed a Fisher’s exact test based on the entire set of expressed genes to compare the observed number of overlapping genes against the expected value under a random distribution. Our analysis demonstrated that the overlap is statistically significant (P < 0.01, OR > 2.5), indicating that the intersecting genes are unlikely to arise by chance. Notably, Tcf7 showed overlapping m3C-seq and RIP-seq signals (Figure 6A). To validate the regulation of METTL8 on Tcf7, a pMigR1-GFP-Tcf7 vector was constructed, and retrovirus was generated to enforce TCF1 expression in Smarta cells. Strikingly, TCF1 overexpression in Mettl8−/− Smarta cells significantly restored the PD-1hiCXCR5hi GC TFH cell frequency (Figure 6, B and C). Correspondingly, the frequency of PD-1loCXCR5+ TFH cells was increased, and that of CXCR5− non-TFH cells was decreased by TCF1 overexpression in Mettl8−/− Smarta cells compared with Mettl8−/− Smarta cells transfected with pMigR1 EV (Supplemental Figure 7I). To test whether METTL8 regulates Tcf7 mRNA stability, an RNA decay assay was performed using actinomycin D and showed that Tcf7 mRNA declined faster in Mettl8-deficient cells than in control cells (Figure 6D), indicating that METTL8 enhances Tcf7 mRNA stability.

METTL8 promotes m3C modification of Tcf7 mRNA and chromatin accessibility iFigure 6

METTL8 promotes m3C modification of Tcf7 mRNA and chromatin accessibility in TFH cells. (A) m³C-seq and METTL8-Flag RIP-seq signals mapped to the Tcf7 transcript. (B and C) Representative plots (B) and quantification (C) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH populations gated on Smarta GFP+CD4+ T cells from the spleens of different recipient mice adoptively transferred with EV or Tcf7 retrovirus-introduced Smarta cells. Mice were infected with LCMV-Armstrong and analyzed at 8 dpi (n = 9–13/group). (D) RNA decay assay showing remaining Tcf7 mRNA detected by RT-qPCR, normalized to t = 0 (n = 2/group). (E) ATAC‑seq heatmaps of local chromatin changes between WT and Mettl8−/− PD-1hiCXCR5hi GC TFH cells. (F) Diamond plots of chromatin interactions in TH1, WT, and Mettl8−/− (KO) TFH cells at the Adar, Il6ra, Ccdc153, and Cxcr5 gene loci (top), with CUT&Tag and ATAC-seq tracks and gene structures on the bottom. Vertical lines with circles denote chromatin loop anchors. (G) Coimmunoprecipitation of TCF1 with METTL8-Flag in HEK293T cells. (H) Representative plots (top) and quantification (bottom) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells gated on CD45.2+ Smarta CD4+ T cells in the spleens of recipient mice transferred with Smarta cells transduced with EV, Mettl8‑WT, or Mettl8‑D220A retrovirus. Mice were infected with LCMV‑Armstrong and analyzed at 8 dpi (n = 6–8/group). (I) TCF1 MFI in CXCR5+ CD4+ TFH cells from the spleens (n = 7–8/group). (J) Immunofluorescence staining showing METTL8 localization in activated CD4+ T cells. Scale bars: 2 μm. Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 1-way ANOVA (C, H, and I) and 2-way ANOVA (D). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Considering the genomic coordination and histone acetylation modification ability of TCF1 (29–31), we performed ATAC-seq (assay for transposase-accessible chromatin with high-throughput sequencing) on Mettl8−/− and control PD-1hiCXCR5hi GC TFH cells and observed reduced chromatin accessibility in Mettl8-deficient GC TFH cells (Figure 6E). The decrease in chromatin accessibility mainly occurred at the gene transcription initiation site (Supplemental Figure 7J). To investigate the cooperation of METTL8 with TCF1 in organizing chromatin architecture (32) in GC TFH cells, we integrated Hi-C (high-resolution chromosome-conformation capture), TCF1 CUT&Tag, and ATAC-seq data from Mettl8−/− and control GC TFH cells with METTL8 CUT&Tag data from Mettl8-tdTomato GC TFH cells. We also performed Hi‑C on TH1 cells to identify TFH‑specific loops affected by METTL8. The analysis identified locus-specific chromatin loops at TCF1 target genes, including Il6ra and Cxcr5, where METTL8 and TCF1 CUT&Tag signals overlapped. These regions also showed H3K27ac enrichment and increased chromatin accessibility, consistent with active regulatory elements at key GC TFH genes (Figure 6F). Notably, these TFH‑specific loops were largely absent in TH1 cells, indicating that the 3D genome organization at these loci is lineage restricted (Figure 6F).

In Mettl8−/− GC TFH cells, TCF1 binding at these loci was substantially reduced, accompanied by disruption of chromatin looping and decreased chromatin accessibility. These findings suggest that METTL8 promotes TCF1-dependent chromatin organization and maintains an accessible regulatory landscape at genes essential for GC TFH cell identity and function (Figure 6F). Together, these results suggest that METTL8 cooperates with TCF1-associated regulatory programs to promote TFH-associated gene expression and chromatin states at TFH-related loci.

To validate the interaction between METTL8 and TCF1, coimmunoprecipitation was conducted using HEK293T cells cotransfected with pMigR1-Mettl8-Flag and pMigR1-Tcf7 plasmids. The results demonstrated that TCF1 coimmunoprecipitated with METTL8 (Figure 6G). Thus, METTL8 can interact with TCF1 protein, supporting a potential mechanism by which METTL8 influences TCF1-associated chromatin accessibility and 3D genome organization.

To determine whether the phenotypic changes in CD4+ T cells are caused by the catalytic activity of METTL8, we used a retroviral transduction system to introduce a point mutation (D220A) at the conserved catalytic residue aspartic acid 220 (27, 28) of METTL8 in Smarta cells. These cells were then adoptively transferred into recipient mice followed by LCMV-Armstrong infection. On day 8 after infection, the D220A mutation abolished the TFH-promoting effect of METTL8 overexpression (Figure 6H) and failed to restore TCF1 expression (Figure 6I). These results suggest that catalytic activity of METTL8 is required for the TFH-promoting function.

Considering that distinct METTL8 isoforms generated by alternative splicing exhibit differential subcellular localization, residing either in the mitochondria or the nucleolus, we investigated METTL8 distribution in CD4+ T cells. Immunofluorescence analysis revealed that METTL8 was present in both the mitochondria and the nucleus (Figure 6J and Supplemental Figure 8C), confirming its dual subcellular localization in this cell type.

Ginkgolic acid suppresses TFH cell responses through a METTL8-associated mechanism. A recent study reported that the nuclear localization of METTL8 was regulated by SUMOylation, which could be completely disrupted by ginkgolic acid (GA), a well-known SUMOylation inhibitor (33). To investigate whether GA affects TFH cell differentiation, we treated LCMV-Armstrong–infected Mettl8-tdTomato-Flag mice with GA (Figure 7A). The data revealed that METTL8 expression reflected by the MFI of tdTomato was significantly decreased in PD-1hiCXCR5hi GC TFH cells upon GA treatment (Figure 7B), suggesting that GA may disrupt METTL8 SUMOylation or METTL8-dependent activity.

GA treatment reduces TFH cell responses without detectably reducing anti–PDFigure 7

GA treatment reduces TFH cell responses without detectably reducing anti–PD-1 antitumor activity. (A) Schematic diagram of GA-treated infection model: Mettl8-tdTomato-Flag mice were infected with LCMV-Armstrong on day 0; treated with GA or vehicle on days 1, 3, 5, and 7; and analyzed on day 8. (B) Representative histograms and quantification of Mettl8-tdTomato reporter MFI in splenic PD-1hiCXCR5hi GC TFH cells (n = 3–4/group). (C) Schematic of the GA-treated adoptive transfer model: CD45.2+ Ctrl or Mettl8–/– Smarta CD4+ T cells were transferred into CD45.1+ WT recipients, followed by LCMV-Armstrong 24 h later, and treated with GA or vehicle every 2 days from days 1 to 7 after infection. Spleen cells were analyzed at 8 dpi. (D and E) Representative plots (D) and quantification (E) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells among donor Smarta cells (n = 5/group). (F) Schematic of the GA or anti–PD-1 antibody treatment. Mice were subcutaneously injected with B16F10 cells, followed by GA and anti–PD-1 treatment alternately from 7 to 12 days after tumor inoculation. (G and H) Tumor growth (G) and survival curve (H) of mice in F (n = 7–8/group). (I) Representative plots (left) and quantification (right) of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (gated on CD44hiCD62Llo CD4+ T cells) in TdLNs of IgG- or anti–PD-1–treated B16F10 tumor–bearing mice, with or without GA (n = 4–5/group). Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using a 2-tailed Student’s t test (B), 1-way ANOVA (E and I), 2-way ANOVA (G), and log-rank test (H). *P < 0.05; **P < 0.01; ***P < 0.001.

To further validate that GA‑mediated suppression of GC TFH cells is associated with METTL8, we treated Mettl8−/− Smarta cell–transferred mice (KO mice) with GA following LCMV infection (Figure 7C). In these KO mice, GA treatment did not alter total lymphocyte or Smarta cell numbers (Supplemental Figure 9, A and B). However, in WT recipients, GA led to a significant decrease in PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells (Figure 7, D and E), along with a reduction in PD-1loCXCR5+ and SLAMloCXCR5+ TFH cells, while the number of CXCR5− non-TFH cells remained unchanged (Supplemental Figure 9, C and D). Similar results were obtained in the direct LCMV infection model (Supplemental Figure 9, E−G). These data indicate that GA inhibits TFH cell differentiation.

Notably, in Mettl8‑deficient mice, the frequencies and absolute numbers of PD-1hiCXCR5hi and BCL6+CXCR5+ GC TFH cells were comparable between GA-treated and untreated groups (Figure 7, D and E), indicating that GA exerts little or no additional effect on GC TFH differentiation in the absence of METTL8. Taken together, these data suggest that GA‑mediated suppression of TFH differentiation is associated with METTL8.

Considering that ICI therapy can trigger autoimmune responses and that neoantigen-driven B cell and TFH cell interactions enhance CD8+ T cell antitumor immunity (34), we further investigated whether GA treatment could adversely affect ICI therapy. Thus, we administered GA in combination with anti–PD-1 antibody in B16F10 and MC38 subcutaneous tumor models (Figure 7F). The addition of GA did not result in a statistically detectable reduction in the antitumor effect of anti–PD-1 (Figure 7, G and H), suggesting that GA does not compromise the antitumor activity of PD-1 blockade. Furthermore, we tested TFH cell development and function following GA treatment and found that GA impaired TFH differentiation and GC response after anti–PD-1 therapy in both B16F10 (Figure 7I and Supplemental Figure 10) and MC38 (Supplemental Figure 11) tumor models. Therefore, GA treatment inhibits TFH response in anti–PD-1 immunotherapy.

In summary, these results identify METTL8 as a key regulator of TFH differentiation via Tcf7 mRNA stabilization and 3D genomic remodeling. Furthermore, genetic loss of METTL8 impairs TFH cell development and function. GA treatment suppresses TFH cell responses in a METTL8‑associated manner.

Discussion

In this study, we identify the m³C methyltransferase METTL8 as a key regulator of TFH cell differentiation in viral infection and tumor immunotherapy models. Using T cell–specific conditional KO mice and adoptive-transfer approaches, we demonstrated that Mettl8 deficiency impairs TFH differentiation and GC responses in the LCMV infection model and following anti–PD-1 immunotherapy in tumor models. In the infection model, these changes were accompanied by reduced antibody production and increased serum viral burden. Mechanistically, METTL8 exerts its effects through a dual mechanism: it stabilizes Tcf7 mRNA in an m³C-associated manner to enhance TCF1 expression and cooperates with TCF1-associated chromatin programs at key TFH-associated loci. Furthermore, we show that pharmacological treatment with GA suppresses TFH responses without a statistically detectable reduction in anti–PD-1 antitumor activity. Collectively, our findings identify METTL8 as an epitranscriptomic regulator that integrates RNA modification, TCF1-associated transcriptional control, and chromatin architecture to orchestrate TFH cell differentiation.

While METTL8 has been characterized as a mitochondria-localized enzyme that catalyzes m³C modification on mitochondrial tRNAs and regulates mitochondrial translation and respiration (16–18), we observed that METTL8 was localized in both the mitochondria and the nucleus in CD4+ T cells. This is consistent with recent reports that alternative splicing generates distinct METTL8 isoforms with differential subcellular localization (35). Notably, our tRNA m³C-seq and Seahorse analyses revealed no significant differences in tRNA m³C modification or mitochondrial respiration between WT and Mettl8-deficient TFH cells, suggesting that the nuclear function of METTL8, rather than a bulk mitochondrial metabolic role, may be primarily responsible for regulating TFH differentiation. This finding is particularly striking given that METTL8 has been implicated in m³C regulation across multiple RNA classes, raising the possibility that its functions depend on cell type, transcript context, and subcellular localization.

The dual mechanism suggested by our data, METTL8-associated stabilization of Tcf7 mRNA and cooperation with TCF1-associated chromatin programs, may represent a coordinated regulatory strategy. This arrangement may help maintain TCF1 at sufficient levels and facilitate engagement of TCF1-associated chromatin programs. Such a dual mechanism may be particularly important for cell fate decisions, where precise and sustained expression of lineage-defining transcription factors is required.

TFH cells play a dual role in human disease: they are essential for protective humoral immunity but also drive autoimmune pathology when dysregulated. Overexpansion of TFH cells leads to excessive GC responses, autoreactive B cell proliferation, and overproduction of high-affinity pathogenic autoantibodies. In the context of cancer immunotherapy, anti–PD-1 treatment expands CXCL13hi GC TFH cells, which can contribute to the development of immune-related adverse events. By identifying METTL8 as a key regulator of TFH differentiation and demonstrating that GA suppresses TFH responses without compromising antitumor immunity, our findings raise the possibility that the METTL8-associated pathway could be explored to limit TFH-driven humoral responses during checkpoint blockade while preserving antitumor activity in selected settings. Direct testing in immune-related adverse event models is required.

The reduction of TFH cells in Mettl8-deficient mice, without detectable impairment of antitumor immunity in these models, suggests that TFH cells are not strictly required for the measured antitumor response under these conditions. Antitumor immune control in these models may rely substantially on CD8+ cytotoxic T lymphocytes, whereas TFH-driven humoral responses may play a subordinate role. Thus, the magnitude of TFH reduction observed here may not be sufficient to affect the overall antitumor response. Alternatively, Mettl8 deficiency may enhance other effector populations, such as TH1 cells, that compensate for diminished TFH help, while residual TFH cells may retain a sufficient helper function. Therefore, TFH contribution to antitumor immunity is context dependent and not universally required, warranting further investigation in distinct tumor models.

Several limitations of this study should be acknowledged. First, while we have demonstrated that GA inhibits TFH differentiation in a METTL8-associated manner, GA is a relatively nonspecific SUMOylation inhibitor that may affect other cellular pathways (36). The development of more specific METTL8 inhibitors would be valuable for therapeutic applications. Second, our mechanistic studies were primarily conducted in the LCMV infection model; whether the same mechanisms operate in the context of cancer or autoimmune diseases remains to be fully established. Third, although we observed that Mettl8 deficiency impaired GC responses and antibody production, the long-term consequences of METTL8 inhibition on humoral immunity and protection against pathogens require further investigation.

GA has been reported to exhibit pleiotropic effects beyond SUMOylation inhibition, including inhibition of fatty acid synthase, nonspecific sirtuin inhibition, and modulation of NF-κB signaling (36). Therefore, while the limited additional effect of GA in Mettl8-deficient cells provides genetic evidence that GA suppresses TFH differentiation at least in part through METTL8, we acknowledge that GA may exert additional METTL8-independent effects in WT cells. The development of more selective METTL8 inhibitors is important to further validate the specificity of this regulatory axis.

In summary, our study identifies METTL8 as an important epitranscriptomic regulator of TFH cell differentiation. The findings support a model in which METTL8 stabilizes Tcf7 mRNA via m³C modification and cooperates with TCF1 protein to organize chromatin architecture at TFH-associated loci. This dual mechanism reinforces proper TFH differentiation and GC responses. Genetic or pharmacological perturbation of the METTL8-associated pathway suppresses TFH responses without detectably compromising antitumor immunity in the tested models, suggesting that this pathway may represent a candidate target for selectively modulating TFH-driven humoral responses in autoimmune diseases and cancer immunotherapy.

Methods

Additional methods may be found in the supplemental material.

Sex as a biological variable. Both male and female mice were used across the study, although individual experiments were not designed or powered for sex-stratified analysis. Therefore, data were pooled across sexes and no sex-stratified analyses were performed.

Mice. Mettl8fl/fl and Mettl8-tdTomato-Flag mice were generated by Shanghai Model Organisms and Cyagen Biosciences, respectively. C57BL/6, B6.SJL (CD45.1), Bcl6fl/fl, Cd4cre, and Smarta mice were from The Jackson Laboratory.

Human samples. Skin from patients with untreated lipomas and those with anti–PD-1–treated lung squamous cell carcinoma was obtained from The First Affiliated Hospital of Chongqing Medical University.

Cell lines. B16F10, MC38 and HEK293T were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). All cell lines tested negative for mycoplasma contamination. MC38 and HEK293T were cultured in DMEM medium (Hyclone). B16F10 cells were cultured in RPMI-1640 medium (Hyclone). All the media were supplemented with 10% FBS (BBI) and 1% penicillin-streptomycin solution (Gibco).

Retroviral constructs and transduction. Mouse Mettl8 and Tcf7 cDNAs were cloned into pMigR1-GFP (Addgene, catalog 27490). The D220A point mutation (GAT→GCT) was introduced into mouse Mettl8 cDNA using primers designed to replace aspartic acid 220 with alanine. Retrovirus was packaged in HEK293T cells as previously described (25). Mettl8–/– or littermate control Smarta mice were primed with LCMV-Armstrong (2 × 106 PFU, i.v.). One day later, splenocytes were spin infected with retrovirus at 1,300 g, 37°C for 90 min, cultured with human IL-2 (100 U/mL) and gp61 peptide (250 nM), and spin infection was repeated the next day. For Tcf7 rescue, 2–5 × 105 retrovirally infected Smarta cells (mixed GFP+ and GFP–) were transferred into CD45.1 recipients, followed by i.v. infection with 2 × 105 PFU LCMV-Armstrong. GFP+ Smarta cells were analyzed at 8 dpi. For cotransfer, 5 × 103 GFP+ or GFP− Smarta cells were sorted, mixed 1:1 (1 × 104 total), transferred, and LCMV-Armstrong infected. For D220A mutation, 1 × 104 GFP+ Smarta cells were transferred and infected similarly.

Preparation of single-cell suspensions, antibody staining, and flow cytometry. Spleens and lymph nodes were crushed through 70 μm cell strainers, and RBCs were lysed. Single-cell suspensions were stained with antibodies as described (37). The fluorochrome-conjugated antibodies were as follows: PE-Cy7 anti-CD19 (1D3, 25-0193-82), PE anti-CD25 (PC61.5, 12-0251-82), PerCP-Cy5.5 anti-CD44 (IM7, 45-0441-82), FITC anti-CD62L (MEL-14, 11-0621-82), APC anti-CXCL13 (DS8CX13, 17-7981-82), APC anti-Fas (15A7, 17-0951-82), PE anti-GL7 (GL7, 12-5902-82), APC anti-ICOS (C398.4A, 17-9949-82), APC anti-IgD (11-26, 17-5993-82), AF660 anti-Ki67 (SolA15, 606-5698-82), APC and PE anti–PD-1 (J43, 17-9985-82 and 12-9985-82), and PE anti–T-bet (4B10, 12-5825-82) from eBiosciences; APC anti-TCF1 (C63D9, 6709S) from Cell Signaling Technology; PE-Cy7 and APC anti-CD45.1 (A20, 110730 and 110714), PE-Cy7 and APC anti-CD45.2 (104, 109830 and 109814), FITC anti-B220 (RA3-6B2, 103206), AF647 anti-BLIMP1 (5E7, 150003), BV421 anti-CXCR5 (L138D7, 145512), and PE anti-SLAM (TC15-12F12.2, 115904) from BioLegend; and BV510 anti-CD4 (RM4-5, 563106), PE anti-CD138 (281-2, 561070), PE anti-BCL6 (K112-91, 561522), and Fixable Viability Stain 780 (565388) from BD Biosciences. For transcription factors, surface-stained cells were fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer Set (eBiosciences) and then stained. Active caspase-3/7 was detected using the Vybrant FAM caspase-3/7 kit (Invitrogen) according to the manufacturer’s instructions. Data were acquired on a Beckman CytoFLEX and analyzed with FlowJo software V10 (TreeStar).

ELISA. Mouse sera were collected at 14 dpi from LCMV-infected Bcl6fl/fl Cd4cre recipients. LCMV-specific serum IgG was measured by ELISA using an mcKLH-conjugated LCMV peptide as the coating antigen (38). In brief, a Nunc MaxiSorp flat-bottom 96-well plate (eBiosciences) was coated with 1 μg/mL Imject mcKLH-conjugated LCMV-specific peptide (Genscript) overnight and then incubated with serially diluted serum samples. The KLH-specific IgG was detected by HRP-conjugated goat-anti-mouse IgG (H+L) secondary antibody (Thermo Fisher Scientific) coupled with TMB substrate (BD Biosciences). The absorbance at 450 nm was read on the INFINITE M NANO microplate reader (TECAN).

H&E staining. For histological analysis, tissues were fixed in 10% neutral buffered formalin for 24–48 h at room temperature, dehydrated through a graded ethanol series, cleared in xylene, and embedded in paraffin wax. Sections were cut at 4 μm thickness using a microtome, mounted on glass slides, and stained with H&E according to standard protocols (39). Images were captured with Pannoramic MIDI (3DHISTECH).

Immunoblotting. The protein expression in cells was determined by Western blotting analysis as described (40). Primary antibodies against the following proteins were used: anti-METTL8 (1:1,000, polyclonal, Novus, NBP2-83196) and anti–β-actin (1:1,000, Cell Signaling Technology, 4970). HRP-linked anti-rabbit (1:3,000, Cell Signaling Technology, 7074P2) secondary antibodies were used. The signaling was imaged with a GE ImageQuant LAS 4000.

m3C AlkAniline-seq library construction. Following the cell sorting strategy of RNA-seq, 1 × 107 TFH cells per sample were prepared. m3C AlkAniline-seq was performed by CloudSeq Biotech (Shanghai, China) according to the published procedure with slight modifications (26). Briefly, for mRNA acquisition, RNA samples were subjected to alkaline hydrolysis for fragmentation. For tRNA acquisition, total RNA was size-selected for small RNA fraction (<200 nt) with the MirVana Isolation Kit (Thermo Fisher Scientific). RNA fragments were dephosphorylated with antarctic phosphatase (New England Biolabs) and then incubated in 1 M aniline for cleavage. RNA libraries were constructed with the GenSeq Small RNA Library Prep Kit following the manufacturer’s instructions. Libraries were controlled for quality and quantified using the BioAnalyzer 2100 system (Agilent Technologies). High-throughput sequencing was performed on an Illumina NovaSeq instrument.

m3C AlkAniline-seq data analysis. Raw data were generated after sequencing, image analysis, base calling, and quality filtering on a sequencer. First, Q30 was used to perform quality control. After adapter-trimming and removing low-quality reads using cutadapt software (v1.9.1), high-quality clean reads were generated. These clean reads were aligned to a reference genome using bowtie2 software (v2.2.4) with end-to-end mode. Raw counts and coverage counts were calculated by bedtools software (v2.24) and in-house scripts and then ratio (defined as: count/coverage) and fold change (defined as: treat-methyl-ratio/input-methyl-ratio) (41) were calculated. Differential m3C sites were calculated based on fold change. The sites were annotated with gene information by bedtools software. Heatmaps were generated using the heatmap.2 function from the R package gplots. The input matrix consisted of logCPM values of differentially expressed tRNAs across samples. Hierarchical clustering was performed using Euclidean distance with average linkage clustering. Scatterplots were generated using log2‑transformed normalized average expression values from the RNA expression table. RNAs with fold changes above the cutoff (default 2.0) were colored red (upregulated) or green (downregulated); those below the cutoff were colored purple.

ATAC-seq data analysis. Bowtie2 with ‘-very-sensitive’ option was used to map the high-quality reads to the mm10 version of the mouse genome. The uniquely properly paired mapped reads were extracted for downstream analysis. MACS2 with the ‘-nomodel’ and ‘-extsize 147’ options was used to call ATAC peaks. DESeq2 was used to identify significantly different (FDR ≤ 0.05) ATAC peaks between different conditions (42).

Hi-C library construction. Following the experimental conditions and cell sorting strategy of RNA-seq, 1 × 106 cells were prepared per sample, each in 2 biological replicates. Hi-C was performed using the Hi-C 3.0 protocol as previously described (43). In brief, the sorted cells were cross-linked with 1% formaldehyde for 10 min at 25°C. The cross-linked cells were lysed in 1 mL lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, and 0.2% NP-40) supplemented with protease inhibitor cocktail (MilliporeSigma) at 4°C for 15 min. The nuclei were collected with 900 μL 1× CutSmart buffer (New England Biolabs) and then treated with 50 μL 0.5% SDS at 62°C for 10 min, followed by adding 25 μL 10% Triton X-100 and 145 μL H2O to quench SDS. The resulting chromatin was then digested with NUB I (New England Biolabs) restriction enzymes at 37°C overnight. The reaction was stopped by incubation at 65°C for 20 min. The DNA ends were blunted and labeled with biotin by Klenow DNA polymerase in the presence of dCTP, dGTP, dTTP, and biotin-14-dATP, followed by ligation using T4 DNA ligase (New England Biolabs). After reverse cross-linking, DNA was fragmented by sonication. The DNA fragments were then end-repaired, and the biotinylated DNA fragments were captured using Dynabeads MyOne Streptavidin C1 beads (Invitrogen, Thermo Fisher Scientific). The DNA on beads was ligated to the TruSeq adapters and amplified with PCR for library construction. DNA fragments of 200–500 bp were purified from 1% E-gel and sequenced on Illumina HiSeq in paired-read mode with a read length of 150 nt.

CUT&Tag data analysis. Cutadapt was used to remove low-quality bases and adapters. Clean reads were mapped to the mm10 genome using bowtie2. MACS2 was used to call CUT&Tag peaks with default settings. The Bam2wig.py script was used to generate bigwig tracks for visualization in IGV (44).

Statistics. Data are presented as mean ± SEM. Two‑group comparisons were performed using 2‑tailed unpaired Student’s t tests, while multiple‑group comparisons were performed using 1-way ANOVA followed by Tukey’s multiple-comparison test. Tumor growth curves were analyzed by 2-way ANOVA, and survival curves were analyzed by the log-rank test. For figures involving multiple comparisons, the specific statistical test applied is detailed in the respective figure legend. Graphs and statistical computations were generated using GraphPad Prism 8.0.2 (GraphPad Software).

Study approval. All animal experiments were reviewed and approved by the Ethics Committee of the University of Science and Technology of China (approval no. USTCACUC192101002). Human skin tissue samples were obtained from patients who provided written informed consent, under protocols approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University (approval no. 2024-581-01).

Data availability. The RNA-seq, m3C-seq, ATAC-seq, TCF1 and H3K27ac CUT&Tag, and Hi-C data from WT and Mettl8–/– TFH cells, along with METTL8-Flag RIP-seq and METTL8 CUT&Tag data from Mettl8-tdTomato-Flag TFH cells, have been deposited at the Gene Expression Omnibus under accession number GSE249068. The spatial transcriptome sequencing data have been deposited at the Genome Sequence Archive (GSA) under accession number HRA020801. As GSA‑Human operates under a controlled-access model in accordance with Chinese regulations on human genetic resources and participant privacy protection, these human data are available upon request from the corresponding author. Numerical source data supporting the figures are provided in the Supporting Data Values file.

Manuscript information

Author contributions. JS performed the experiments and analyzed the data with help from JW, XQ, JM, HY, QL, JY, YD, and HM. DC and JL analyzed the RNA-seq, ATAC-seq, TCF1, METTL8 and H3K27ac CUT&Tag, Hi-C, and scRNA-seq data. TH, XH, and XS provided the Hi-C library construction platform and technical support. RY, XZ, and QC provided paraffin-embedded skin sections and spatial transcriptomic profiling of skin tissues. BL and LY provided key technical support and experimental materials. FL, JL, QH, and HW supervised the overall studies and compiled the manuscript. The order of the co-first authors was determined by their relative contributions to the study. JS performed the majority of the experiments, data analysis, and manuscript writing and is therefore listed first. DC analyzed the ATAC-seq, CUT&Tag, Hi-C, and scRNA-seq data and is listed second.

AI disclosure. DeepSeek was used for language polishing during the review period from May to June 2026.

Conflict of interest. The authors have declared that no conflict of interest exists.

Funding. This study was supported by the following:

  • The Ministry of Science and Technology of China (2023YFC2306400 to FL).
  • University of Science and Technology of China Research Funds of the Double First-Class Initiative (YD9100002508 to FL).
  • State Key Laboratory of Immune Response and Immunotherapy 2025 (SE2550000001 to FL).
  • Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of the Institute of Health and Medicine (QYPY20230027 to FL).
  • National Natural Science Foundation of China (82370148 to JL and 82322031 to QH).
  • R&D Program of Guangzhou National Laboratory (GZNL2023A02011 to JL).
  • Natural Science Foundation of Chongqing (CSTB2024NSCQ-JQX0008 to QH).
Supplemental material

View Supplemental data

View Unedited blot and gel images

View Supporting data values

Acknowledgments

We thank Lilin Ye (The Institute of Immunology, Third Military Medical University, Chongqing, China) for providing the Bcl6fl/fl mice and LCMV-Armstrong as well as Shuyang Yu (China Agricultural University, Beijing, China) for providing the Smarta mice.

Address for correspondence. Fengyin Li, 443 Huangshan Road, University of Science and Technology of China, Anhui, China. Phone: 86.0551.63600939; Email: fyli88@ustc.edu.cn. Or: Jia Li, 151 Yanjiang West Road, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China. Phone: 86.19878341601; Email: jiali@gzhmu.edu.cn. Or: Qizhao Huang, 1 Yixueyuan Road, Chongqing Medical University, Chongqing, China. Phone: 86.13648303833; Email: huangqizhaotcell@cqmu.edu.cn. Or: Hua Wang, 81 Meishan Road, Anhui Medical University, Anhui, China. Phone: 86.0551. 65161057; Email: wanghua@ahmu.edu.cn.

Footnotes

Copyright: © 2026, Song et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2026;136(22):e199747.https://doi.org/10.1172/JCI199747.

References
  1. Shulman Z, et al. T follicular helper cell dynamics in germinal centers. Science. 2013;341(6146):673–677.
    View this article via: CrossRef PubMed Google Scholar
  2. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185–189.
    View this article via: CrossRef PubMed Google Scholar
  3. Zhu F, et al. Spatiotemporal resolution of germinal center Tfh cell differentiation and divergence from central memory CD4+ T cell fate. Nat Commun. 2023;14(1):3611.
    View this article via: CrossRef PubMed Google Scholar
  4. Greczmiel U, et al. Sustained T follicular helper cell response is essential for control of chronic viral infection. Sci Immunol. 2017;2(18):eaam8686.
    View this article via: CrossRef PubMed Google Scholar
  5. Künzli M, Masopust D. CD4+ T cell memory. Nat Immunol. 2023;24(6):903–914.
    View this article via: CrossRef PubMed Google Scholar
  6. Sautès-Fridman C, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–325.
    View this article via: CrossRef PubMed Google Scholar
  7. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.
    View this article via: CrossRef PubMed Google Scholar
  8. Herati RS, et al. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat Immunol. 2022;23(8):1183–1192.
    View this article via: CrossRef PubMed Google Scholar
  9. Baumjohann D, Brossart P. T follicular helper cells: linking cancer immunotherapy and immune-related adverse events. J Immunother Cancer. 2021;9(6):e002588.
    View this article via: CrossRef PubMed Google Scholar
  10. Baumeister SH, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34(1):539–573.
    View this article via: CrossRef PubMed Google Scholar
  11. Choi YS, et al. LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6. Nat Immunol. 2015;16(9):980–990.
    View this article via: CrossRef PubMed Google Scholar
  12. Shao P, et al. Cutting edge: Tcf1 instructs T follicular helper cell differentiation by repressing Blimp1 in response to acute viral infection. J Immunol. 2019;203(4):801–806.
    View this article via: CrossRef PubMed Google Scholar
  13. Leong YA, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17(10):1187–1196.
    View this article via: CrossRef PubMed Google Scholar
  14. Podestà MA, et al. Stepwise differentiation of follicular helper T cells reveals distinct developmental and functional states. Nat Commun. 2023;14(1):7712.
    View this article via: CrossRef PubMed Google Scholar
  15. Bélanger S, et al. The chromatin regulator Mll1 supports T follicular helper cell differentiation by controlling expression of Bcl6, LEF-1, and TCF-1. J Immunol. 2023;210(11):1752–1760.
    View this article via: CrossRef PubMed Google Scholar
  16. Kleiber N, et al. The RNA methyltransferase METTL8 installs m3C32 in mitochondrial tRNAsThr/Ser(UCN) to optimise tRNA structure and mitochondrial translation. Nat Commun. 2022;13(1):209.
    View this article via: CrossRef PubMed Google Scholar
  17. Schöller E, et al. Balancing of mitochondrial translation through METTL8-mediated m3C modification of mitochondrial tRNAs. Mol Cell. 2021;81(23):4810.
    View this article via: CrossRef PubMed Google Scholar
  18. Zhang F, et al. Epitranscriptomic regulation of cortical neurogenesis via Mettl8-dependent mitochondrial tRNA m3C modification. Cell Stem Cell. 2023;30(3):300–311.
    View this article via: CrossRef PubMed Google Scholar
  19. Lee S-A, et al. METTL8 mRNA methyltransferase enhances cancer cell migration via direct binding to ARID1A. Int J Mol Sci. 2021;22(11):5432.
    View this article via: CrossRef PubMed Google Scholar
  20. Law C, et al. Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus. Nature. 2024;631(8022):857–866.
    View this article via: CrossRef PubMed Google Scholar
  21. Bocharnikov AV, et al. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019;4(20):e130062.
    View this article via: JCI Insight CrossRef PubMed Google Scholar
  22. Li YM, et al. Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease. Ann Rheum Dis. 2023;82(10):1348–1358.
    View this article via: CrossRef PubMed Google Scholar
  23. Choi YS, et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol. 2013;190(8):4014–4026.
    View this article via: CrossRef PubMed Google Scholar
  24. Suprunenko T, Hofer MJ. Complexities of type I interferon biology: lessons from LCMV. Viruses. 2019;11(2):172.
    View this article via: CrossRef PubMed Google Scholar
  25. Li F, et al. Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf. Nat Commun. 2018;9(1):5452.
    View this article via: CrossRef PubMed Google Scholar
  26. Marchand V, et al. AlkAniline-seq: profiling of m7G and m3C RNA modifications at single nucleotide resolution. Angew Chem Int Ed Engl. 2018;57(51):16785–16790.
    View this article via: CrossRef PubMed Google Scholar
  27. Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206.
    View this article via: CrossRef PubMed Google Scholar
  28. Zhao J, et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell. 2010;40(6):939–953.
    View this article via: CrossRef PubMed Google Scholar
  29. Xing S, et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat Immunol. 2016;17(6):695–703.
    View this article via: CrossRef PubMed Google Scholar
  30. Li F, et al. TFH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function. Proc Natl Acad Sci U S A. 2020;118(2):e2014562118.
    View this article via: CrossRef PubMed Google Scholar
  31. Shan Q, et al. Tcf1–CTCF cooperativity shapes genomic architecture to promote CD8+ T cell homeostasis. Nat Immunol. 2022;23(8):1222–1235.
    View this article via: CrossRef PubMed Google Scholar
  32. Shan Q, et al. Tcf1 and Lef1 provide constant supervision to mature CD8+ T cell identity and function by organizing genomic architecture. Nat Commun. 2021;12(1):5863.
    View this article via: CrossRef PubMed Google Scholar
  33. Zhang L-H, et al. The SUMOylated METTL8 induces R-loop and tumorigenesis via m3C. iScience. 2020;23(3):100968.
    View this article via: CrossRef PubMed Google Scholar
  34. Cui C, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184(25):6101–6118.
    View this article via: CrossRef PubMed Google Scholar
  35. Huang M, et al. Molecular basis for human mitochondrial tRNA m3C modification by alternatively spliced METTL8. Nucleic Acids Res. 2022;50(7):4012–4028.
    View this article via: CrossRef PubMed Google Scholar
  36. Borenstein R, et al. Ginkgolic acid inhibits fusion of enveloped viruses. Sci Rep. 2020;10(1):4746.
    View this article via: CrossRef PubMed Google Scholar
  37. Song J, et al. Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s. Hepatology. 2022;75(5):1181–1193.
    View this article via: CrossRef PubMed Google Scholar
  38. Shan Q, et al. The transcription factor Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage. Nat Immunol. 2017;18(8):931–939.
    View this article via: CrossRef PubMed Google Scholar
  39. Cardiff RD, et al. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014;2014(6):655–658.
    View this article via: CrossRef PubMed Google Scholar
  40. Song H, et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12(1):5522.
    View this article via: CrossRef PubMed Google Scholar
  41. Schwartz S, et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell. 2014;159(1):148–162.
    View this article via: CrossRef PubMed Google Scholar
  42. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–359.
    View this article via: CrossRef PubMed Google Scholar
  43. Lafontaine DL, et al. Hi-C 3.0: improved protocol for genome-wide chromosome conformation capture. Curr Protoc. 2021;1(7):e198.
    View this article via: CrossRef PubMed Google Scholar
  44. Zhang Y, et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 2008;9(9):R137.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (November 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Manuscript information
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts